Frontlight ResearchEarly access
Systemic sclerosis (scleroderma) trials in United States
39 of 53 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 1Not yet taking people in United StatesBAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease
- Where
- Boston
- Age
- 16 years to 75 years
- People
- 94
- Run by
- Luminary Therapeutics
See details and how to joinNCT07729995 - No phaseTaking peopleDiffuse Cutaneous Scleroderma (DSSc) SFDI Study
- Where
- Boston
- Age
- 18 years and over
- People
- 65
- Run by
- Boston University
See details and how to joinNCT07090226 - Phase 1Taking peopleA Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Where
- Boston, Durham
- Age
- 18 years and over
- People
- 125 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07115745 · EU 2024-517681-41-00 - Phase 2Taking peopleA Study of Microbiome Transplantation for the Treatment of Constipation and/or Significant Bloating in Patients With Systemic Sclerosis
- Where
- Houston
- Age
- 18 years and over
- People
- 21
- Run by
- The University of Texas Health Science Center, Houston
See details and how to joinNCT06827977 - No phaseTaking peopleSystemic Sclerosis DIet for GastrointESTinal Symptoms
- Where
- Ann Arbor
- Age
- 18 years and over
- People
- 60
- Run by
- University of Michigan
See details and how to joinNCT07402226 - Phase 1Taking peopleUS Zamto-cel Autoimmune Diseases
- Where
- Milwaukee
- Age
- 18 years and over
- People
- 48
- Run by
- Miltenyi Biomedicine GmbH
See details and how to joinNCT06708845 - Phase 1Taking peopleA Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Where
- Beverly Hills, Cleveland, Durham, Fullerton, Gainesville, Irvine, Los Angeles, Louisville, Memphis, Miami, Minneapolis, New York, Oklahoma City, Omaha, Philadelphia, San Francisco
- Age
- 12 years to 70 years
- People
- 244 worldwide
- Run by
- Fate Therapeutics
See details and how to joinNCT06308978 - Phase 2Taking peopleIntralesional Injection of STS in Treatment of Calcinosis
- Where
- Pittsburgh
- Age
- 18 years and over
- People
- 20
- Run by
- Robyn T. Domsic, MD, MPH
See details and how to joinNCT06672822 - Phase 2Taking peopleA Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
- Where
- Ann Arbor, Arlington
- Age
- 18 years and over
- People
- 162 worldwide
- Run by
- Galderma R&D
See details and how to joinNCT07047690 · EU 2025-522294-11-00 - Phase 4Not yet taking people in United StatesOpen Label Treprostinil Raynaud's Study
- Where
- Boston
- Age
- 18 years and over
- People
- 30
- Run by
- Brigham and Women's Hospital
See details and how to joinNCT07112183 - Phase 1Enrolling by invitationA Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease
- Where
- Buffalo, Redwood City
- Age
- 18 years to 80 years
- People
- 180
- Run by
- Adicet Therapeutics
See details and how to joinNCT06375993 - No phaseTaking peopleThe Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life
- Where
- Ann Arbor, Nashville, New Orleans, Pittsburgh
- Age
- 18 years and over
- People
- 160
- Run by
- Robyn T. Domsic, MD, MPH
See details and how to joinNCT06675344 - No phaseTaking peopleInterrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis
- Where
- Houston
- Age
- 18 years and over
- People
- 60
- Run by
- The University of Texas Health Science Center, Houston
See details and how to joinNCT05989763 - Phase 2Taking peopleStudy to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- Where
- Charleston, Chicago, Cleveland, Dallas, Houston, Los Angeles, Miami, New Orleans, New York, Oklahoma City, Richmond, Salt Lake City, San Diego
- Age
- 18 years and over
- People
- 25
- Run by
- aTyr Pharma, Inc.
See details and how to joinNCT05892614